Our Co-Founder and CEO, Chere Chapman, took the stage at AAIC 2025 in Toronto, Ontario with an oral presentation titled "Evaluating the Feasibility of a Personalized Endpoint in Down Syndrome-Associated Alzheimer's Disease: Inventory-Facilitated Goal Attainment Scaling." The presentation provided an overview of the results of the Longitudinal Investigation for the Enhancement of Down Syndrome Research (LIFE-DSR) study, which was conducted in collaboration with the longtime partner,  LuMind IDSC Foundation.